Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2020)
Historic Retained Earnings for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to -$30.1 million.
- Monopar Therapeutics' Retained Earnings fell 2181.67% to -$30.1 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$30.1 million, marking a year-over-year decrease of 2181.67%. This contributed to the annual value of -$25.9 million for FY2019, which is 1950.93% down from last year.
- As of Q3 2020, Monopar Therapeutics' Retained Earnings stood at -$30.1 million, which was down 2181.67% from -$28.4 million recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Retained Earnings registered a high of -$1.9 million during Q4 2016, and its lowest value of -$30.1 million during Q3 2020.
- For the 5-year period, Monopar Therapeutics' Retained Earnings averaged around -$21.9 million, with its median value being -$23.0 million (2019).
- In the last 5 years, Monopar Therapeutics' Retained Earnings tumbled by 88391.27% in 2017 and then tumbled by 1710.46% in 2020.
- Over the past 5 years, Monopar Therapeutics' Retained Earnings (Quarter) stood at -$1.9 million in 2016, then tumbled by 883.91% to -$18.4 million in 2017, then dropped by 17.52% to -$21.7 million in 2018, then dropped by 19.51% to -$25.9 million in 2019, then fell by 16.14% to -$30.1 million in 2020.
- Its Retained Earnings was -$30.1 million in Q3 2020, compared to -$28.4 million in Q2 2020 and -$27.0 million in Q1 2020.